(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 216.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Renovorx's revenue in 2026 is $1,123,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $149,156,180, with the lowest RNXT revenue forecast at $121,479,572, and the highest RNXT revenue forecast at $174,353,612. On average, 6 Wall Street analysts forecast RNXT's revenue for 2027 to be $566,468,936, with the lowest RNXT revenue forecast at $198,784,754, and the highest RNXT revenue forecast at $1,094,533,198.
In 2028, RNXT is forecast to generate $1,759,988,828 in revenue, with the lowest revenue forecast at $954,933,111 and the highest revenue forecast at $2,250,775,314.